Charles River Laboratories (CRL) Misses Q3 EPS by 1c; Tightens FY11 EPS Outlook
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $185.00 --0%
Revenue Growth %: -5.1%
Financial Fact:
Continuing operations (in dollars per share): 0.79
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -5.1%
Financial Fact:
Continuing operations (in dollars per share): 0.79
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Charles River Laboratories Int'l (NYSE: CRL) reported Q3 EPS of $0.57, $0.01 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $277.6 million versus the consensus estimate of $280.45 million.
Charles River Laboratories sees FY2011 EPS of $2.40-$2.45, versus prior guidance of $2.38-$2.48 and the consensus of $2.45.
Charles River Laboratories sees FY2011 EPS of $2.40-$2.45, versus prior guidance of $2.38-$2.48 and the consensus of $2.45.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Upgrades Charles River Labs (CRL) to Overweight, 'strong uptick in biopharma funding beginning to transition into RFPs and bookings'
- Pfizer reaffirms 2026 guidance after CFO transition news
- Ennis (EBF) Reports In-Line Q1 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
